Benitec Biopharma rang the Nasdaq opening bell Friday.
The company marked the start of trading at the exchange incelebration of its initial public offering.
The company's CEO, Peter French, did the honors.
Based in Australia, Benitec develops treatments for Hepatitis B and C, lung cancer and other chronic and life- threatening diseases, according to the company's website.
Read MoreCRH Medical rings NYSE opening bell
Benitec trades on the Nasdaq under the ticker symbol BNTC.